



AREV NANOTEC BRANDS INC.
PRESS RELEASE

AREV NANOTEC COMPLETES PHASE 1 OF MUSHROOM EXTRACTION JOINT VENTURE WITH ABSOLEM HEALTH

VANCOUVER, BC / January 26, 2021 / AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) (“AREV Brands”) is pleased to announce that it has completed the first stage of its Joint Venture agreement with Absolem Mushroom Extraction Inc. (“Absolem”) (a subsidiary of Absolem Health Inc.) as announced July 17, 2020, where Absolem selected AREV Brands to develop an exclusive extraction method for functional and medicinal mushrooms. Absolem has paid CAD \$20,000 as its cash portion for participation in the Joint Venture and issued 2,133,334 shares of Absolem Health Inc. to AREV Brands. AREV Brands has utilized the cash payment to acquire certain extraction equipment that will be utilized to conduct research for the benefit of Absolem. Financially, AREV Brands owns 50% of the Joint Venture and holds a 6.6% equity interest in Absolem Health Inc. and accordingly will earn participatory revenues from the sale of extracts utilizing its equipment and SOP’s.

The Company has taken delivery of the pharmaceutical grade nanotechnology equipment and integrated it into its proprietary extraction systems. As the Company’s work has identified green solvents suitable for extraction of functional and medicinal fungi and commenced trials on optimizing extraction of phyto-compounds found in lions mane. Lions mane was selected as the initial mushroom to work with due to its legal status and unique functional properties for mental health, particularly dementia.

AREV’s extraction system and proprietary methods enable the extraction of a variety of specific natural active substances, which are naturally present in certain functional and medicinal mushrooms. It is these natural substances that are reputed to have fostered and created some of the beneficial claims, when certain types of mushroom species are ingested by humans as noted in many peer reviewed papers. In the second phase of this Joint Venture, AREV Brands is focused on the beneficial features that are attributed to **Hericium erinaceus**, more commonly known as the “lion’s mane” mushroom. “This mushroom has a long history of use in traditional Chinese medicines, and it has recently been examined in formal Western medicinal studies with the conclusion that lion’s mane appears to be a “good candidate to regress recognition memory decline during aging...and could be a new therapeutic strategy for preventing or treating neurodegenerative diseases such as dementia and Alzheimer’s.” “Heridium erinaceus Improves Recognition Memory and Induces Hippocampal and Cerebellar Neurogenesis in Frail Mice during Aging”. *Source “Nutrients”, March 2019.

Both Absolem and AREV Brands are aware of the numerous additional naturally occurring wild and/or cultivated mushrooms in existence, and we are currently expanding our focus accordingly.

The technology that is being created and utilized for this extraction is a result of certain permutations and combinations available within AREV Brands extraction facility. Each “refinement” procedure is being specifically designed for the extraction of the natural substance that is to be ultimately used as an active ingredient for an intended analgesic or possible solution to the particular health condition that is under review.

Plants and fungi might be viewed as natural “factories” which produce a broad variety of diverse compounds. Reported results of both human and animal use of these products have been recorded throughout history. Some of the information is in historic testimonial form and some is presented in Western scientific formats. Relief of specific ailments provided from natural substances have been recorded ranging from temporary to permanent. Evidence of relief has been ob-



served to occur throughout a variety of conditions of painful discomfort, including some amount of relief provided for anti-inflammatory situations, immune support, anti-biotic, oxidant, anxiety, nausea, depression and PTSD.

AREV Brands has begun to extract the ingredient(s) known to have been involved in the relief, perhaps only temporary, of symptoms currently experienced by a significant portion of the human and animal world.

Some Observations on Process Scale Extraction:

The isolation and extraction of the substance(s) that produce positive results in a living being is an age old process. Extractions are achieved via, fermentation, straining, filtration, centrifugal force, gravity, ultrasound, ethanol usage, water usage and numerous combinations of these and other activities.

Plants and fungi are natural chemical factories that produce diverse natural compounds: anti-inflammatory, immune support, anti-viral, antibiotic, anti-cancer, analgesics, antioxidants, anxiety reduction, treatment for depression, and preservation of memory.

Process scale extraction allows multi-kilogram quantities of functional oils and fractionated materials from plants and fungi to be produced. All intellectual property generated through the extraction methods research, which relate to mushroom extraction methods will vest in Absolem and all other intellectual property shall vest in AREV Brands. This will include any scientific information related to organic chemistry extraction technologies.

Mr. Withrow has successfully established a cultivation lab and culture facility for growing Cordyceps in Ho Chi Minh City, Vietnam. His former company has four (4) NPN's for Cordyceps registered with Health Canada. Mr. Withrow commented that "Completion of Phase 1 gives AREV Brands a stake in the exciting new functional and medicinal mushroom sectors via our holdings in Absolem." He went on to say, "We now are on the way to being able to deliver a proprietary extraction method to the Absolem Extraction JV as planned."

For further information, contact Mike Withrow, mike@AREVBrands.com 778-929-6536.

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Inc.

AREV NanoTec Brands Inc. ("AREV") produces and sells functional ingredients produced via its proprietary extraction systems. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition markets. AREV's model is to toll process extraction of targeted essential and functional oils and license its formulations to Licensed Producers in Canada. The company utilizes toll processors in foreign countries to encapsulate and package its formulations that can be sold in traditional distribution channels and online.

About Absolem Mushroom Extraction Inc.

Absolem is a company focused on the health and wellness benefits derived from extracts from a variety of functional and medicinal mushrooms.



NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.